Jefferies analyst Roger Song raised the firm’s price target on United Therapeutics (UTHR) to $575 from $564 and keeps a Buy rating on the shares. The firm notes the company put out another revenue record quarter, with Tyvaso as key driver. Also, the company is open to various partnerships such as ex-U.S. for Tyvaso and relinepag with potential to combo with other MOA including Winrevair. Overall, Jefferies believes the set-up is even stronger following the quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics: Strong Growth Potential Amid Short-Term Volatility Supports Buy Rating
- Morning Movers: Nvidia jumps after GTC, Trump comments
- United Therapeutics reports Q3 EPS $7.16, consensus $6.96
- Notable companies reporting before tomorrow’s open
- United Therapeutics’ Promising Study on Inhaled Treprostinil for Lung Disease